SILO PHARMA, INC. Deferred Revenue Recognized
SILO PHARMA, INC. (SILO) reported Deferred Revenue Recognized of $838 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-05-14
- SILO PHARMA, INC. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $838.00, a 0.00% change year-over-year.
- SILO PHARMA, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $838.00.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-03-31 | $838.00 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $3.35K POS AM · filed 2026-04-14 | |||
| 2025-09-30 | $2.51K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $1.68K 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $838.00 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $3.35K POS AM · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |